Genetic Characterization of the Immortalized Human Nasopharyngeal Carcinoma Cell Line NPC/HK1

IF 2.9 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-02-04 DOI:10.1002/cam4.70422

Anna Makowska, Udo Kontny, Josef van Helden, Barbara Hildebrandt, Herdit M. Schüler, Ralf Weiskirchen

{"title":"Genetic Characterization of the Immortalized Human Nasopharyngeal Carcinoma Cell Line NPC/HK1","authors":"Anna Makowska, Udo Kontny, Josef van Helden, Barbara Hildebrandt, Herdit M. Schüler, Ralf Weiskirchen","doi":"10.1002/cam4.70422","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Human nasopharyngeal carcinoma (NPC) cell lines are in vitro model systems that are widely available, easy to handle, and provide an unlimited supply of material. They also bypass ethical concerns associated with the use of primary human cells or tissue. However, many of these cell lines including 5-8F, 6-10B, CNE-1, CNE-2, HNE-1, HONE-1, SUNE1, SUNE2, and NPC-TW01 have been shown to be misidentified or cross-contaminated. While simple molecular genotyping techniques such as short tandem repeat profiling of human cell lines are available to confirm cell line identity, scientists often do not implement strategies to avoid misidentification. This has resulted in a large volume of publications containing incorrect information.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this paper, we have established a cell line karyogram that contains several marker chromosomes and a set of typical aberrations characteristic of NPC/HK1.</p>\n </section>\n \n <section>\n \n <h3> Results and Conclusions</h3>\n \n <p>Combined with the typical multiloci short tandem repeat signature of NPC/HK1, the cytogenetic analysis provides an effective means to avoid unreliable experimental outcomes and scientific misinterpretation.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 3","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70422","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70422","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Human nasopharyngeal carcinoma (NPC) cell lines are in vitro model systems that are widely available, easy to handle, and provide an unlimited supply of material. They also bypass ethical concerns associated with the use of primary human cells or tissue. However, many of these cell lines including 5-8F, 6-10B, CNE-1, CNE-2, HNE-1, HONE-1, SUNE1, SUNE2, and NPC-TW01 have been shown to be misidentified or cross-contaminated. While simple molecular genotyping techniques such as short tandem repeat profiling of human cell lines are available to confirm cell line identity, scientists often do not implement strategies to avoid misidentification. This has resulted in a large volume of publications containing incorrect information.

Methods

In this paper, we have established a cell line karyogram that contains several marker chromosomes and a set of typical aberrations characteristic of NPC/HK1.

Results and Conclusions

Combined with the typical multiloci short tandem repeat signature of NPC/HK1, the cytogenetic analysis provides an effective means to avoid unreliable experimental outcomes and scientific misinterpretation.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.